Sol-Gel Technologies Ltd. (SLGL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alon Seri-Levy | Co-Founder, CEO & Director | 411k | -- | 1961 |
| Mr. Gilad Mamlok | Chief Financial Officer | 367k | -- | 1968 |
| Dr. Itzik Yosef | Chief Operating Officer | 236k | -- | 1976 |
| Mr. Moshe Arkin | Executive Chairman of the Board | -- | -- | 1953 |
| Prof. David Avnir | Co-Founder | -- | -- | -- |
| Ms. Tamar Fishman Jutkowitz | VP & General Counsel | -- | -- | 1976 |
| Dr. Karine Neimann | VP of Projects & Planning and Chief Chemist | -- | -- | 1971 |
Sol-Gel Technologies Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Corporate Governance
Recent Events
- Mar 20, 2024POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingSee Full Filing
- Mar 13, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 06, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 29, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 23, 20246-K: Corporate Changes & Voting MattersSee Full Filing